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A Meta-Analysis of Histomorphometric Results and Graft
Healing Time of Various Biomaterials Compared
to Autologous Bone Used as Sinus Floor
Augmentation Material in Humans
Reinoud J. Klijn, M.Sc.,1 Gert J. Meijer, D.D.S., Ph.D.,1,2 Ewald M. Bronkhorst, Ph.D.,3
and John A. Jansen, D.D.S., Ph.D.1
Background: To date, no studies have been published in which histomorphometric data from a large group of
patients comparing various biomaterials for sinus floor augmentation procedures were evaluated.
Materials and Methods: A meta-analysis of the English literature from January 1993 till April 2009 was carried
out. Out of 147 titles, according to our criteria, 64 articles were selected for analysis describing the use of
autologous bone and their alternatives, such as allogenic, xenogenic, and alloplastic materials.
Results: On the basis of autologous bone grafting, a reference value for total bone volume (TBV) of 63% was
found. Particulation of the bone graft resulted in a general reduction of 18% in TBV. Delayed implant
placement reduced the TBV with 7%. Overall TBV was 8% or 6% higher if a biopsy was, respectively, taken
before 4.5 months or after 9.0 months after initial sinus augmentation surgery. Allogenic, xenogenic, alloplastic,
or combinations of graft materials all resulted in a significant lower amount of TBV compared to autologous
bone grafting ranging from 7% to 26%. Inventorying the effect of ‘‘biopsy time’’ for autologous bone, the TBV
was significantly higher before 4.5 and after 9.0 months of healing time compared to period in between.
Surprisingly, no significant differences in TBV with respect to ‘‘biopsy time’’ for bone substitutes were found.
Conclusions: On the basis of the aspect of TBV autologous bone still has to be considered to be the gold standard
in sinus augmentation surgery. However, the consequence of the TBV for implant survival is still unraveled yet.
Introduction
Sinus floor augmentation surgery has become a rou-tine procedure to generate primary implant placement
and stability in the lateral part of the maxilla, resulting in an
implant survival rate of 90% for 3 to 5 years.1–7 Autologous
bone is the most commonly used graft material and, as such,
still considered to be the gold standard.8,9 Unfortunately,
harvesting an autologous bone graft is associated with several
disadvantages. Donor-site surgery requires prolonged oper-
ating time and may cause morbidity.10–14 To avoid serious
advents of taking iliac crest bone transplants, such as hyper-
sensitivity,15 pelvic instability, infection,14,16 and paraesthe-
sia,17 the mandibular symphysis has been advocated as an
alternative donor site13,18–20; however, grafting chin bone may
induce complications as well, such as paraesthesia21 and apical
root damage.12,22 In contrast to intraoral donor sites, a relative
larger amount of bone is available in the iliac crest that can be
harvested in multiple forms (particles, strips, and blocks).
To overcome the disadvantages of autologous bone
grafting in sinus augmentation surgery, various allogenic,
xenogenic, and alloplastic graft materials or combination of
these materials have been tested, followed by variable re-
sults.23 Demineralized freeze-dried bone allograft (DFDBA)
and also mineralized freeze-dried bone allograft (MFDBA) are
obtained from cadaver bone that is cleaned and chemically
treated.24 Both have been proven to be biocompatible and
osteoconductive25 and are harvested in the same matter, with
the only difference that the DFDBA material undergoes the
additional step of decalcification. This also accounts for an-
organic deproteinized bovine bone,26 which is a xenogenic
bone graft from which all organic components have been
removed,27 although still small amounts of proteins may be
present, including growth factors such as transforming growth
factor-b and bone morphogenetic protein (BMP)-2.28 Further
alloplastic materials have been investigated. As such, promis-
ing results for bioactive glass (BG) composites were reported.29
Their bioactivity stimulates the reparative process,30 resulting
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in a relatively fast bone ingrowth compared to for example
hydroxyapatite (HA).31 HA, either hydrothermally con-
verted from coral or synthetically manufactured, shows a
crystalline spatial structure close to that of cortical bone
matrix32 and it is considered to be osteoconductive.27,33
The degradation of HA is relatively slow and is related to the
amount of porosity of the material; it may dissolute at
the surface or resorb by the activity of macrophages and
multinucleated giant cells.34,35 Pure-phase beta-tricalcium
phosphate (b-TCP), as a derivate of HA, has been shown to
be completely resorbable and, in addition, is simultaneously
replaced by new bone formation.36,37 For the sake of com-
pleteness, also calcium sulfate, calcium carbonate, hydrogels,
biodegradable polymers, and tissue-engineered constructs,
either combined with growth factors or cultured cells, are
described in the literature as graft material in human sinus
floor augmentation. Except for the selected biomaterial, other
variables may also influence the final outcome.38 For exam-
ple, some authors advise to apply a resorbable or non-
resorbable barrier membrane over the sinus graft osteotomy
site,39–42 or propagate immediate or delayed placement
of dental implants. Others recommend a prolonged graft
healing time.7
It is reported that a higher percentage of bone volume
results in a higher implant–bone contact, thereby resulting in
a higher implant survival.38 Further, the percentage of total
bone volume (TBV) formed is an important parameter of the
performance of a bone graft or bone replacement graft in
an augmented sinus.24,43–45 Till now, no studies have been
published that evaluated histological and histomorphometric
data related to different biomaterials and their variables from
a large group of patients. Therefore, to answer which graft
material results in the highest TBV in human sinus floor
augmentation surgery and which graft healing time is the
most optimal, a meta-analysis was conducted.
Materials and Methods
Search protocol and selection of articles
An online and manual search was conducted of the
Medline database from January 1993 till April 2009 using the
PubMed search machine entering the following search terms:
‘‘(maxillary) sinus augmentation or (maxillary) sinus lift’’ and
‘‘human or clinical or patient’’ and ‘‘histology or histomor-
phometry or histomorphometric.’’ A hand search was per-
formed in the following journals: Clinical Oral Implant
Research, International Journal of Oral and Maxillofacial Im-
plants, International Journal of Periodontics and Restorative
Dentistry, and The Journal of Periodontology. As well, the ref-
erences of the retrieved articles were searched. The results
were limited to humans and to articles published in the
English literature. Articles were only regarded eligible if they
included lateral sinus augmentation surgery in which an
autogenic, allogenic, xenogenic, or alloplastic graft material,
solely or in combination, was placed. Further, histomor-
phometric data about TBV needed to be present. Effects
elucidated by a graft mixture with >90% volume of one
biomaterial were fully accounted to that specific biomaterial,
except if platelet-rich plasma (PRP) was added. Each re-
trieved citation was reviewed by two independently work-
ing reviewers. Most articles were excluded on the basis of
information provided by the title or abstract. If the citation
could not be excluded unequivocally, any disagreement was
resolved by consensus. To ensure consistency of the results
for the included studies, clear definitions of outcome were
defined. For example, TBV was based on histomorphometric
data as a percentage of the whole field of view. Subse-
quently, the included studies were carefully analyzed con-
cerning data on ‘‘graft material,’’ ‘‘biopsy time,’’ ‘‘block
grafting technique,’’ ‘‘particulated grafting technique,’’ the
usage of a ‘‘(non)-resorbable membrane’’ over the lateral
window, ‘‘immediate or delayed’’ implant placement, and
TBV. Where adequate data were available, subgroups of
similar interventions were identified. At least five subgroups,
including at least two sinus floor augmentations per group,
describing a graft material or combination of graft materials,
had to be reported in the literature to include their data in
this analysis.
Meta-analysis
Linear regression, a form of meta-analysis, was performed
to determine the effect of the independent variables: ‘‘graft
material,’’ ‘‘biopsy time,’’ ‘‘block grafting technique,’’ ‘‘parti-
culated grafting technique,’’ the usage of a ‘‘(non)-resorbable
membrane’’ over the lateral window, and ‘‘immediate or
delayed’’ implant placement on the histomorphometric out-
come after maxillary sinus floor augmentation. The amount
of TBV was used as the dependent variable. To evaluate the
general influence of ‘‘biopsy time’’ on the histomorphometric
data outcome, all data were equally divided into three dif-
ferent groups of time: 0–4.5 months, 4.5–9 months, and
longer than 9 months. The reference group comprised the use
of an autologous bone graft with a biopsy time between 4.5
and 9 months, immediate implant placement, and no mem-
brane use. The overall averages were controlled for study
characteristics and weighted by study size.
A second linear regression was performed to correct the
found TBV for each graft material or combination of graft
materials, for ‘‘biopsy time.’’ All subgroups were divided
into three subgroups based on biopsy time: 0–4.5 months,
4.5–9 months, and longer than 9 months. The amount of TBV
was used as the dependent variable. Independent variables
were ‘‘block grafting technique,’’ ‘‘particulated grafting
technique,’’ the usage of a ‘‘(non)-resorbable membrane’’ over
the lateral window, and ‘‘immediate or delayed implant
placement.’’ The reference group was identical. All effects
have been corrected for different parameters inside the
model by linear regression and group size. The outcome,
among corresponding p-values, had to be summed and re-
calculated for the groups with combined use of different
graft materials in sinus augmentation surgery.
Results
The basis search provided 147 titles for consideration. As a
result, 64 articles met our inclusion criteria. Describing au-
tologous bone,29,36,37,39,41,42,46–64 addition of PRP,47,52,55
DFDBA,65–69 MFDBA,24,25,68,70–73 anorganic deproteinized
bovine bone,24,26,48,53,60,62,69,74–85 bioactive glass
(BG),29,56,86,87 synthetic HA,53,64,81,82,88–90 coral-derived
HA,91,92 b-TCP,36,37,54,58–60,85,93–95 and combinations of
these materials.24,42,48,49,60,62,67,69,78,87,95–98 The majority of
these 64 articles were prospective controlled studies (48).
Only eight randomized clinical trials met the inclusion
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criteria, followed by eight case series (Table 1). In total, his-
tomorphometric data were obtained from 1677 grafted si-
nuses divided in 172 subgroups. As a result, 11 material
groups were recognized of similar bone graft or combination
of bone graft materials (Table 2). A specific overview of these
subgroups is provided in Tables 3–13. Graft materials were
used as blocks, particulated grafts, or as combination of both.
The topic of using (non)-resorbable barrier membranes over
the lateral wall was addressed in 24 out of the 64 articles.
Statistical analysis
In total, 17 variables entered into the regression model as
depicted in Table 14 along with their p-values and confidence
intervals. The R2 for the full model was 0.460; the adjusted
R2 was 0.403.
Graft material. After linear regression a reference value
for TBV of 63% was calculated. Most graft materials showed
significant differences in TBV compared to this reference
value (Table 14) (Fig. 1). The addition of PRP to an autolo-
gous bone graft reduced the TBV with 18.0%. Usage of a
xenogenic bone graft decreased the TBV with 13%, while
usage of a xenogenic bone graft combined with autologous
bone resulted in a less decrease of 8%. The confidence in-
tervals showed a significant overlap, indicating that the ad-
dition of autologous bone made no statistically significant
difference. Combining DFDBA with a xenogenic bone graft,
however, resulted in a significant lower TBV, as a decrease of
25% compared to the reference was found. Combining BG
with autologous bone resulted in a 17% decrease, and
combining b-TCP with autologous bone resulted in a re-
duction of 9% in TBV. Sinus floor augmentation with
synthetically manufactured HA or hydrothermally con-
verted coral reduced TBV with 11% or 12% respectively.
Further, almost significant, MFDBA and b-TCP resulted both
in a TBV decrease of 7%. Thus, most bone substitutes, even
mixed with autologous bone, resulted in a significant lower
TBV compared to the reference value of 63% for autologous
bone. On the other hand, taken into account that the confi-
dence intervals of most substitutes had a significant overlap,
the difference between them regarding amount of TBV was
not statistically significant. This, however, did not account
for DFDBA with a xenogenic bone graft.
Biopsy time. There is significant evidence that the TBV
was influenced by graft healing time in general and thus the
‘‘biopsy time’’ of all samples. Overall TBV was 8% or 6%
higher if a biopsy was, respectively, taken before 4.5 months
or after 9.0 months after the sinus augmentation surgery.
After performing the second linear regression (Table 15),
correcting each bone graft material for ‘‘biopsy time,’’ a
summation had to be made for the combined use of graft
materials with their corresponding p-values (Table 16).
Only in case of autologous bone grafting and the com-
bined use of autologous bone with a xenogenic bone graft,
‘‘biopsy time’’ had a significant influence on the TBV: a bi-
opsy time of <4.5 months resulted in an increase in TBV of
11% compared to a biopsy taken between 4.5 and 9.0
months. Additionally, a biopsy time of 9.0 months or longer
increased the TBV with 10% compared to the centered group.
Further, the combined use of autologous bone and a xeno-
genic bone graft started with a plus of 26% of TBV compared
to the period between 4.5 and 9 months. Surprisingly, no
further significant difference could be detected between the
various graft materials in time.
Variables. Compared to the reference value of TBV, us-
age of a particulated graft significantly decreased the TBV
with 18%, while usage of a block resulted in an decrease of
6% TBV, although not to a significant level. In addition,
‘‘delayed’’ implant placement, significantly resulted in a
lower TBV of 7% compared to ‘‘immediate’’ implant
placement. Further, no evidence was found that the use of a
resorbable membrane over the lateral window had any ef-
fect, positive or negative, on the amount of TBV.
Discussion
Maxillary sinus floor augmentations are ideal test sites to
histomorphometricaly assess a grafted material. Before pre-
paring the implant bed to install dental implants, a biopsy of
the reconstructed area can be easily taken, implicating no
extra burden for the patient. As an additional advantage this
procedure can be performed under local anesthesia. In the
selected studies various bone substitutes were used, or solely
or as a bone graft extender in combination with autologous
bone. Till now, autologous bone grafts are considered to be
the gold standard.8,9 This postulation, however, is only based
on implant survival, while bone quality in the grafted area is
Table 1. Literature Overview
n
‘‘Sinus Augmentation’’
or ‘‘Sinus Lift’’
428 hits
AND (human or
patient or clinical)
401 hits
AND (histology or histomorphometric
or histomorphometry
147 hits
Included 64 articles
Randomized clinical trails 8 articles
Prospective controlled trials 48 articles
Case series 8 articles
Table 2. Overview of Grafting Materials
Material n subgroups n sinusses
Autologous bone graft 47 438
PRP 7 35
MFDBA 7 96
ADBB 29 319
ADBBþ autologous bone 29 261
ADBBþDFDBA 9 113
Synthetic HA 10 108
Phycogenic HA 9 52
b-TCP 8 116
b-TCPþ autologous bone 7 62
Bioactive glassþ autologous bone 8 72
Total
P
170 1672
PRP, platelet-rich plasma; MFDBA, mineralized freeze-dried bone
allograft; ADBB, anorganic deproteinized bovine bone; DFDBA,
demineralized freeze-dried bone allograft; HA, hydroxyapatite;
b-TCP, beta-tricalcium phosphate.
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Table 3. Overview of Autologous Bone Grafting
Author Year Graft type n sinusses Membrane
Immediate
or delayed
Biopsy time
(months) TBV
Lundgren 1996 Particulate 10 None Delayed 0 45.00
Lundgren 1996 Block 10 None Delayed 0 58.00
Pejrone 2002 Block 26 None Delayed 0 59.30
Lorenzetti 1998 Block 8 None Delayed 0 60.00
Lorenzetti 1998 Particulate 3 None Delayed 0 65.60
Lorenzetti 1998 Block 3 None Delayed 0 65.60
Thor 2007 Particulate 11 None Delayed 3 11.00
Zerbo 2003 Block 5 Collagen Delayed 3 39.38
Raghoebar 2005 Blockþparticulate 5 None Delayed 3 41.10
Consolo 2007 Particulate 2 None Delayed 4 26.00
Zerbo 2003 Block 6 Collagen Delayed 4 39.78
Tadjoedin 2000 Particulate 3 None Delayed 4 40.94
Lorenzetti 1998 Block 3 None Delayed 4 62.60
Consolo 2007 Particulate 2 None Delayed 5 29.20
Crespi 2007 Particulate 6 Collagen Delayed 5 34.00
Tadjoedin 2000 Particulate 3 None Delayed 5 42.24
John 2004 Particulate 2 None Delayed 5 53.50
John 2004 Particulate 2 None Immediate 5 53.50
Crespi 2007 Particulate 10 Collagen Delayed 5 69.70
Barone 2005 Particulate 18 Collagen Delayed 5 70.00
Crespi 2009 Particulate 15 None Delayed 5 78.40
Gerressen 2009 Particulate 15 None Delayed 5 29.35
Gerressen 2009 Particulate 15 None Delayed 5 37.87
Thor 2007 Particulate 11 None Delayed 6 13.00
Groeneveld 1999 Particulate 3 None Delayed 6 26.20
Van den Bergh 2000 Particulate 3 None Delayed 6 26.60
Consolo 2007 Particulate 2 None Delayed 6 29.00
Szabo 2001 Particulate 4 None Delayed 6 37.05
Szabo 2005 Particulate 20 None Delayed 6 38.34
Lundgren 1996 Particulate 10 None Delayed 6 40.00
Scarano 2006 Particulate 16 None Delayed 6 40.10
Zerbo 2003 Block 3 Collagen Delayed 6 40.90
Zerbo 2004 Particulate 5 None Delayed 6 41.00
Zijderveld 2005 Particulate 6 None Delayed 6 41.00
Tadjoedin 2000 Particulate 3 None Delayed 6 43.65
Lorenzetti 1998 Particulate 8 None Delayed 6 53.00
Pejrone 2002 Block 26 None Delayed 6 54.10
Suba 2006 Particulate 17 None Delayed 7 34.70
Consolo 2007 Particulate 2 None Delayed 7 20.00
Turunen 2004 Blockþparticulate 17 None Delayed 7 25.10
Simunek 2008 Particulate 8 None Delayed 9 49.20
Le Lorc’h-Bukiet 2005 Particulate 24 None Delayed 10 49.40
Lorenzetti 1998 Particulate 3 None Delayed 11 69.30
Turunen 2004 Blockþparticulate 17 None Delayed 12 25.10
Lundgren 1996 Particulate 10 None Delayed 12 48.00
Pejrone 2002 Block 26 None Delayed 12 63.90
Hallman 2002 Particulate 11 None Delayed 13 37.30
TBV, total bone volume.
Table 4. Overview of Addition of Platelet-Rich Plasma
Author Year Graft name Graft type n sinusses Membrane
Immediate
or delayed
Biopsy time
(months) TBV
Thor 2007 ABGþPRP Particulate 11 None Delayed 3.0 22.00
Raghoebar 2005 ABGþPRP Blockþparticulate 5 None Delayed 3.0 38.40
Consolo 2007 ABGþPRP Particulate 2 None Delayed 4.0 43.30
Consolo 2007 ABGþPRP Particulate 2 None Delayed 5.0 39.30
Thor 2007 ABGþPRP Particulate 11 None Delayed 6.0 14.00
Consolo 2007 ABGþPRP Particulate 2 None Delayed 6.0 29.00
Consolo 2007 ABGþPRP Particulate 2 None Delayed 7.0 20.00
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often left out of consideration.7,27 Further, implant survival
and bone quality may be confounded by factors other than
the graft material.7,38 The aim of this study was to give a
powerful estimate of the true effect of the various variables:
‘‘graft material,’’ ‘‘biopsy time,’’ ‘‘block grafting technique,’’
‘‘particulated grafting technique,’’ the usage of a ‘‘(non)-
resorbable membrane’’ over the lateral window, and
‘‘immediate or delayed’’ implant placement, on the histo-
morphometric outcome after sinus floor augmentation sur-
gery. Because of the general absence or differences of other
histomorphometric indices in the studies, TBV was solely
used as dependent variable.
Graft material
Autologous bone. Compared to autologous bone, for each
biomaterial or combination of graft materials in sinus aug-
mentation surgery a significant lower TBV was found. Evi-
dently, autologous bone grafting resulted in the highest
percentage of mineralized bone. It should, however, be em-
phasized that when evaluating biopsies from autologous-bone-
grafted areas, not only the new bone formation but also the
transplanted bone volume is scored. This in contrast to exam-
ining biopsies from sites reconstructed with bone substitutes,
from which only the newly formed bone can be measured.
Table 5. Overview of Mineralized Freeze-Dried Bone Allograft
Author Year Graft name Graft type n sinusses Membrane
Immediate
or delayed
Biopsy time
(months) TBV
Choukroun 2006 FDBA Particulate 3 None Delayed 4.0 20.31
Stacchi 2008 FFB Particulate 10 Collagen Delayed 5.0 48.15
Kassolis 2005 FDBA Particulate 10 Collagen Delayed 5.3 26.50
Froum 2006 Puros Particulate 13 Collagen Delayed 6.6 28.25
Kolerman 2008 FDBA Particulate 23 Collagen Delayed 9.0 29.09
Noumbissi 2005 Puros Particulate 6 None Delayed 9.0 40.33
Cammack 2005 FDBA Particulate 31 (Non)-resorbable Delayed 11.2 41.07
Table 6. Overview of Anorganic Deproteinized Bovine Bone (ADBB) Grafting
Author Year Graft name Graft type n sinusses Membrane
Immediate
or delayed
Biopsy time
(months) TBV
Wheeler 1996 Interpore 200 Particulate 4 None Delayed 4.00 12.02
Orsini 2006 Cortical pig bone Particulate 10 Collagen Delayed 5.00 36.00
John 2004 Bio Oss Particulate 7 None Delayed 5.50 29.52
John 2004 Bio Oss Particulate 14 None Immediate 5.50 29.52
Yildirim 2000 Bio Oss Particulate 3 Collagen Delayed 6.00 13.15
Lee 2006 Bio Oss Particulate 14 Collagen Delayed 6.00 18.30
Valentini 2000 Bio Oss Particulate 20 None Delayed 6.00 21.08
Mangano 2007 Bio Oss Particulate 20 None Immediate 6.00 36.20
Scarano 2006 PepGen P-15 Particulate 16 None Delayed 6.00 37.00
Scarano 2006 Bio Oss Particulate 16 None Delayed 6.00 39.00
Yildirim 2000 Bio Oss Particulate 2 Collagen Delayed 6.50 19.15
Froum 2006 Bio Oss Particulate 13 Collagen Delayed 6.60 12.44
Cordaro 2008 Bio Oss Particulate 23 Collagen Delayed 6.70 19.80
Yildirim 2000 Bio Oss Particulate 2 Collagen Delayed 7.00 10.85
Ozyuvaci 2003 Bio Oss Particulate 20 None Immediate 7.00 47.50
Froum 2008 Bio Oss Particulate 11 Collagen Delayed 7.17 22.30
Froum 1998 Osteograft/n Particulate 5 None Delayed 7.50 8.50
Yildirim 2000 Bio Oss Particulate 2 Collagen Delayed 7.50 15.25
Froum 1998 Osteograft/n Particulate 10 None Delayed 7.50 17.00
Springer 2006 Bio Oss Particulate 5 None Delayed 8.00 25.00
Yildirim 2000 Bio Oss Particulate 2 Collagen Delayed 9.00 16.50
Simunek 2008 Bio Oss Particulate 10 None Delayed 9.00 34.20
Wheeler 1996 Interpore 200 Particulate 2 None Delayed 10.00 25.10
Lee 2006 Bio Oss Particulate 14 Collagen Delayed 12.00 26.60
Valentini 2000 Bio Oss Particulate 20 None Delayed 12.00 27.55
Artzi 2002 Bio Oss Block 10 Collagen Immediate 12.00 34.20
Artzi 2001 Bio Oss Particulate 4 Collagen Delayed 12.00 42.10
Artzi 2001 Bio Oss Particulate 16 Collagen Immediate 12.00 42.10
Hallman 2002 Bio Oss Particulate 14 Collagen Delayed 14.50 41.70
Traini 2008 Bio Oss Particulate 10 None Delayed 20.00 38.00
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Platelet-rich plasma. Platelets are a natural source of
growth factors. Some authors state that the combined use of
growth factors and graft material will introduce osteogenesis
and improve bone healing,99 whereas others reject the ad-
junctive use PRP in sinus augmentation because of disap-
pointing results.100,101 In this study, the addition of PRP to a
autologous bone graft generally resulted in a significant
lower TBV. In the literature, the regenerative potential of
PRP seemed to be restricted to shorter treatment times.47
However, in this meta-analysis, no significance evidence was
found that PRP has a positive effect on TBV during graft
healing time. To date, none of the studies, describing the use
of growth factors, for example, BMP-2, BMP-7, or trans-
forming growth factor-b, fulfilled the inclusion criteria.
Allogeneic bone. DFDBA was always used in combina-
tion with a xenogenic bone graft and resulted in the lowest
TBV as compared to autologous bone and all other materials.
Grafting with MFDBA has a tendency to result in a slightly
lower TBV compared to autologous bone, but not to a sig-
nificant level. Also in case of MFDBA, it must be noted that
particles of nonresorbed MFDBA are described to be difficult
to distinguish as graft material from new vital bone in the
calculation of TBV.24
Xenogenetic bone. The addition of autologous bone to a
xenograft resulted in a slight increase in TBV compared to its
single use, but not to a significant level. This increase in TBV
ranged between 15% till 50%.42,60 As the ratio of xenogenic
Table 7. Overview of ADBB Grafting and Autologous Bone
Author Year Graft name Graft type
n
sinusses Membrane
Immediate
or delayed
Biopsy time
(months) TBV
Tadjoedin 2003 Bio OssþABG 1:5 Particulate 2 None Delayed 5.0 37.30
Barone 2005 OsteobiolþABG 1:1 Particulate 18 Collagen Delayed 5.0 67.00
John 2004 Bio OssþABG 66:33 Particulate 7 None Delayed 5.5 32.23
John 2004 Bio OssþABG 66:33 Particulate 6 None Immediate 5.5 32.23
Wheeler 1996 Interpore 200þABG Particulate 2 None Delayed 6.0 4.72
Yildirim 2001 Bio OssþABG Particulate 2 Collagen Delayed 6.0 15.17
Yildirim 2001 Bio OssþABG Particulate 2 Collagen Delayed 6.0 15.67
Wheeler 1996 Interpore 200þABG Particulate 2 None Delayed 6.0 23.00
Galindo-Moreno 2008 Bio OssþABG 1:1 Particulate 5 Collagen Delayed 6.0 31.02
Yildirim 2001 Bio OssþABG Particulate 2 Collagen Delayed 6.5 18.27
Yildirim 2001 Bio OssþABG Particulate 2 Collagen Delayed 6.5 20.62
Hallman 2001 Bio OssþABG 18:82 Particulate 20 None Delayed 6.7 31.40
Hallman 2001 Bio OssþABG 18:82 Particulate 20 None Delayed 6.7 31.40
Wheeler 1996 Interpore 200þABG Particulate 3 None Delayed 7.0 14.82
Wheeler 1996 Interpore 200þABG Particulate 2 None Delayed 7.0 15.60
Froum 1998 Osteograft/nþABG Particulate 7 None Delayed 7.5 18.50
Froum 1998 Osteograft/nþABG Particulate 31 None Delayed 7.5 29.00
Wallace 2005 Bio OssþABG 5:1 Particulate 6 None Delayed 8.0 12.10
Wallace 2005 Bio OssþABG 5:1 Particulate 21 e-PTFE Delayed 8.0 16.90
Wallace 2005 Bio OssþABG 5:1 Particulate 37 Collagen Delayed 8.0 17.60
Moy 1993 Interpore 200þABG 1:1 Blockþparticulate 4 None Delayed 8.0 44.40
Wheeler 1996 Interpore 200þABG Particulate 2 None Delayed 9.0 12.60
Yildirim 2001 Bio OssþABG Particulate 2 Collagen Delayed 9.0 18.88
Simunek 2008 Bio OssþABG 85:15 Particulate 10 None Delayed 9.0 24.40
Lorenzetti 1998 Interpore 200þABG 1:1 Particulate 3 None Delayed 12.0 43.60
Artzi 2005 Bio OssþABG Particulate 2 Collagen Delayed 12.0 45.60
Artzi 2005 Bio OssþABG Particulate 10 Collagen Immediate 12.0 45.60
Hallman 2002 ABGþBio Oss 1:4 Particulate 11 None Delayed 12.5 39.90
Hallman 2001 ABGþBio Oss 18:82 Particulate 20 None Delayed 36.0 51.50
e-PTFE, expanded polytetrafluoroethylene.
Table 8. Overview of ADBB and Demineralized Freeze-Dried Bone Allograft Graft
Author Year Graft name Graft type n sinusses Membrane
Immediate
or delayed
Biopsy time
(months) TBV
Hanisch 1999 Osteograft/nþDFDBA 1:1 Particulate 20 None Delayed 6.0 8.10
Froum 1998 Osteograft/nþDFDBA Particulate 8 None Delayed 7.5 14.00
Froum 1998 Osteograft/nþDFDBA Particulate 14 None Delayed 7.5 23.00
Moy 1993 InterporeþDBP 200 7:1 Blockþparticulate 2 None Delayed 8.0 4.60
Hanisch 1999 Osteograft/nþDFDBA 1:1 Particulate 20 None Delayed 8.0 9.00
Noumbissi 2005 Bio OssþDFDBA 1:1 Particulate 4 None Delayed 9.0 38.75
Hanisch 1999 Osteograft/nþDFDBA 1:1 Particulate 20 None Delayed 10.0 11.80
Landi 2000 Osteograft/nþDFDBA 1:1 Particulate 5 None Delayed 10.3 27.92
Hanisch 1999 Osteograft/nþDFDBA 1:1 Particulate 20 None Delayed 12.0 20.70
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bone mineral versus autologous bone graft increases, re-
sorption of the bone additive decreases exponentially, be-
cause less osteoclasts can be recruited from the autogenous
bone.27,102 A reduced resorption may have negative conse-
quences on the mechanical properties of the augmented bone
and its capacity to support an implant, since the augmented
bone will be a composite rather than a homogenous bone
structure.27,103 Obviously, this is the case for all bone sub-
stitutes.
Alloplastic bone substitutes. A variety of alloplastic bone
substitutes, single or in combination with autologous bone,
was used in sinus augmentation surgery. In this study the
effect of BG, synthetic HA, coral-derived HA, and b-TCP on
the amount of TBV was investigated. Although alternative
materials were described in the literature, they did not met
the inclusion criteria stated for this meta-analysis. To add the
osteogenic and osteoinductive components that are neces-
sary to achieve complete bone formation, the bone substi-
tutes were occasionally mixed with autogenous
bone.24,42,48,49,60,62,67,69,78,87,95–98 Further, in larger defects the
bone additive reduces the required autologous bone needed.
BG was used in combination with autologous bone in
ratios of 1:1, and 1:4. BG is a resorbable particulate synthetic
bioactive glass from which the granules are supposed to
function as small bone regenerative chambers.104 Un-
expectedly, after linear regression, sinus augmentation with
BG resulted in the lowest TBV of all alloplastic materials.
Table 9. Synthetic Hydroxyapatite
Author Year Graft name Graft type
n
sinusses Membrane
Immediate
or delayed
Biopsy time
(months) TBV
Canullo 2009 Nanobone Particulate 8 None Delayed 3.0 8.00
Crespi 2009 SINTlife Particulate 15 None Delayed 5.0 29.65
Scarano 2006 Fin granule HA Particulate 16 None Delayed 6.0 32.00
Mangano 2007 Porous synthetic HA Particulate 20 None Immediate 6.0 34.70
Mangano 2006 Engipore Blockþparticulate 11 None Delayed 6.0 38.50
Canullo 2009 Nanobone Particulate 8 None Delayed 6.0 48.00
Artzi 2003 Osteogen Particulate 2 Collagen Delayed 12.0 28.10
Artzi 2003 Osteogen Particulate 8 Collagen Immediate 12.0 28.10
Artzi 2001 Osteogen Particulate 4 Collagen Delayed 12.0 32.20
Artzi 2001 Osteogen Particulate 16 Collagen Immediate 12.0 32.20
Table 10. Overview of Coral-Derived Hydroxyapatite
Author Year Graft name Graft type n sinusses Membrane
Immediate
or delayed
Biopsy time
(months) TBV
Simunek 2005 Algipore Particulate 3 None Delayed 6.0 10.90
Simunek 2005 Algipore Particulate 3 None Immediate 6.0 20.10
Ewers 2005 Algipore Particulate 29 Various Delayed 7.1 28.95
Simunek 2005 Algipore Particulate 3 None Delayed 9.0 25.00
Simunek 2005 Algipore Particulate 3 None Immediate 9.0 31.70
Simunek 2005 Algipore Particulate 2 None Delayed 12.0 33.50
Simunek 2005 Algipore Particulate 3 None Immediate 12.0 34.80
Simunek 2005 Algipore Particulate 3 None Delayed 15.0 30.20
Simunek 2005 Algipore Particulate 3 None Immediate 15.0 51.10
Table 11. Overview of Beta-Tricalcium Phosphate
Author Year Graft name Graft type n sinusses Membrane
Immediate
or delayed
Biopsy time
(months) TBV
Zerbo 2004 Cerasorb Particulate 9 None Delayed 6.0 17.00
Zijderveld 2005 Cerasorb Particulate 10 None Delayed 6.0 17.00
Szabo 2001 Cerasorb Particulate 8 None Delayed 6.0 29.37
Szabo 2005 Cerasorb Particulate 40 None Delayed 6.0 36.47
Suba 2006 Cerasorb Particulate 17 None Delayed 6.5 32.38
Ozyuvaci 2003 b-TCP Particulate 20 None Immediate 7.0 52.50
Zerbo 2001 Cerasorb Particulate 2 None Delayed 8.0 20.00
Simunek 2008 Cerasorb Particulate 10 None Delayed 9.0 21.40
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Sinus augmentation with synthetic or coral-derived HA also
resulted in a decrease of TBV. As HA was grafted without
the addition of autologous bone, TBV was only influenced by
new bone formation from the local sinus environment. For
b-TCP with or without the addition of autologous bone,
TBV differed not significantly. While others stated that along
with the replacement of solely b-TCP, the TBV will conse-
quently increase,58 this postulation, however, could not be
confirmed by this meta-analytical study. Also, the influence
of adding autologous bone to b-TCP appeared to be negli-
gible, although supplemented in 10% to 50% of the total graft
volume.60,93,95
All bone graft substitutes, alone or in combination with an
autologous bone graft, resulted in a analogous significant
lower TBV compared to autologous bone grafting. On the
other hand, taken into account that the confidence intervals
Table 12. Overview of Beta-Tricalcium Phosphate and Autologous Bone
Author Year Graft name Graft type n sinusses Membrane
Immediate
or delayed
Biopsy time
(months) TBV
Knabe 2008 b-TCPþABG Particulate 10 None Delayed 6.0 26.70
Knabe 2008 b-TCPþABG Particulate 10 None Delayed 6.0 31.70
Knabe 2008 b-TCPþABG Particulate 10 None Delayed 6.0 35.50
Knabe 2008 b-TCPþABG Particulate 10 None Delayed 6.0 40.30
Simunek 2008 CerasorbþABG Particulate 10 None Delayed 9.0 24.00
Artzi 2005 b-TCPþABG Particulate 3 Collagen Delayed 12.0 32.00
Artzi 2005 b-TCPþABG Particulate 9 Collagen Immediate 12.0 32.00
Table 13. Overview of Bioactive Glass
Author Year Graft name Graft type
n
sinusses Membrane
Immediate
or delayed
Biopsy time
(months) TBV
Tadjoedin 2000 BGþABG 1:1 Particulate 3 None Delayed 4.0 28.45
Tadjoedin 2000 BGþABG 1:1 Particulate 3 None Delayed 5.0 34.54
Galindo-Moreno 2008 BGþABG 1:1 Particulate 5 Collagen Delayed 6.0 33.08
Tadjoedin 2000 BGþABG 1:1 Particulate 3 None Delayed 6.0 38.07
Turunen 2004 BG S53P4þABG Particulate 17 None Delayed 7.0 25.70
Cordioli 2001 BGþABG 4:1 Particulate 12 Collagen Immediate 10.8 14.20
Cordioli 2001 BGþABG 4:1 Particulate 12 Collagen Immediate 10.8 30.60
Turunen 2004 BG S53P4þABG Particulate 17 None Delayed 12.0 28.80
Table 14. Regression Analysis 1
Unstandardized coefficients 95% confidence interval for B
Model B Std. Error Sig. Lower bound Upper bound
1 (Constant) 62.66 8.28 0.00 52.77 85.48
Particulated graft 17.89 5.64 0.00 29.02 6.76
Block graft 5.85 4.79 0.22 15.31 3.62
Membrane 13.14 8.05 0.10 29.04 2.75
Resorbable membrane 11.47 8.18 0.16 4.68 27.62
Delayed implantology 6.46 2.91 0.03 12.20 0.72
Biopsy t< 4.5 months 8.41 2.56 0.00 3.35 13.47
Biopsy t> 9.0 months 5.57 2.13 0.01 1.35 9.78
PRP 17.96 6.27 0.01 30.33 5.59
MFDBA 7.30 4.52 0.11 16.23 1.63
ADBB 12.74 3.02 0.00 18.71 6.77
ADBBþAutologous 8.26 3.13 0.01 14.44 2.09
ADBBþDFDBA 25.31 3.97 0.00 33.16 17.47
Synthetic HA 11.30 4.10 0.01 19.40 3.20
Coral-derived HA 11.50 5.48 0.04 22.32 0.67
b-TCP 6.53 4.04 0.11 14.50 1.45
b-TCPþ autologous 9.19 5.00 0.07 19.06 0.69
Bioactive glassþ autologous 16.82 4.79 0.00 26.28 7.35
Dependent variable: TBV.
Example: Calculation of expected TBV for ‘‘Particulated synthetic HA with a resorbable membrane and immediate implantology
and a biopsy time of <4.5 months’’¼ 62.66 – (17.89 – 11.3þ 11.47þ 8.41)¼ 53.35%.
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of most substitutes had a significant overlap, the differences
between them regarding amount of TBV were not signifi-
cant.
In a recent review by Nkenke and Stelzle, the current lit-
erature was analyzed to determine whether there are ad-
vantages of using autogenous bone over bone substitutes in
sinus floor augmentation with respect to implant survival.
They concluded that no evidence was present that neither
supports nor refutes the superiority of autologous bone
grafts over other graft materials with regard to implant
survival.7 In our study, there is a significant difference be-
tween autologous bone and their alternatives with respect to
the TBV. However, the higher TBV apparently does not re-
sult in a higher implant survival.7 Therefore, when using
bone substitutes, it is still unclear what the minimal TBV is
for a grafted sinus to guarantee implant survival.
Biopsy time
In literature it is reported that up to 33% of the autologous
bone graft may resorb during the initial 6 months after sinus
floor augmentation surgery.47,51,105,106 This decrease in TBV
affects the primary implant stability and therefore, as this
effect of significant initial bone resorption may persist for
years,107–109 is a serious problem. In this meta-analysis, au-
tologous graft resorption resulted in a significant lower TBV
between 4.5 and 9.0 months. Hereafter, the TBV raised to
same level of TBV, as scored in the first 4.5 months.
For the combination anorganic deproteinized bovine bone
(ADBB) and autologous bone, biopsies taken in the first 4.5
months after initial surgery resulted in a significant higher TBV
compared to biopsies taken at a later time point. Surprisingly,
addition of autologous bone to the other bone substitutes did
not result into this boost effect; the TBV did not significantly
alter in time. Recently, Nkenke and Stelzle concluded in a re-
view that implant survival seemed not to be influenced by the
healing period of the graft material.7 This is in analog with our
finding that in case of using bone substitutes, the TBV is
constant in time. Because of the wide variation and absence of
other (cellular) histomorphometric indices in studies, no fur-
ther conclusion could be drawn about resorption, bone appo-
sition of remodeling in time in our study.
Variables
After statistical analysis, particulation of the graft resulted
in a significant lower amount of TBV, but there was no such
evidence for block grafting. Almost all grafted materials
were used in a particulated structure. Occasionally, autolo-
gous bone was used as block graft, but only a few articles
compared block versus particulate grafting.26,39,49–52,56,67,88
Placement of endosseous dental implants is done either
simultaneously or after a certain time period to allow for
consolidation of the grafted material. Simultaneous implant
placement is less invasive and more effective.110 Also, ‘‘de-
layed’’ implant placement resulted in a significant decrease
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FIG. 1. Overview of the effect of type of grafting material on total bone volume compared to the reference (Table 14).
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of TBV compared to ‘‘immediate’’ implant placement.
However, residual alveolar ridge height and implant stabil-
ity should be the decisive argument for the decision of staged
implant placement.111
Another examined variable was the use of a membrane
over the lateral window of the sinus. Tarnow et al. reported
that the placement of an expanded polytetrafluoroethylene
(e-PTFE) barrier membrane tends to increase vital bone for-
mation.112 Others suggested that this effect also can be
achieved using a poly(lactic acid) membrane.113 In a meta-
analysis on the survival of endosseous dental implants,
Wallace and Froum concluded that membrane utilization is a
Table 15. Regression Analysis 2
Unstandardized coefficients 95% confidence interval for B
Model B Std. error Sig. Lower bound Upper bound
1 (Constant) 62.20 8.41 0.00 52.29 85.52
Particulated graft 18.91 5.54 0.00 29.86 7.95
Block graft 7.52 4.73 0.11 16.87 1.82
Membrane 8.16 7.96 0.31 23.90 7.57
Resorbable membrane 7.31 8.08 0.37 8.65 23.27
Delayed implantology 6.70 2.99 0.03 12.60 0.80
PRP t< 4.5 months 4.18 12.28 0.73 20.09 28.46
PRP t¼ 4.5–9.0 months 19.79 9.22 0.03 38.01 1.57
Autologous t< 4.5 months 10.86 3.79 0.00 3.37 18.34
Autologous t> 9 months 9.52 4.31 0.03 0.99 18.05
MFBBA t< 4.5 months 6.74 11.78 0.57 16.55 30.03
MFBBA t¼ 4.5–9.0 months 7.49 10.11 0.46 27.48 12.50
MFBBA t> 9 months 8.07 10.39 0.44 12.46 28.60
ADBB t< 4.5 months 1.17 6.29 0.85 11.27 13.61
ADBB t¼ 4.5–9.0 months 10.82 3.96 0.01 18.65 3.00
ADBB t> 9 months 6.19 4.24 0.15 2.19 14.57
ADBBþ autologous t< 4.5 months 14.83 7.55 0.05 0.10 29.76
ADBBþ autologous t¼ 4.5–9.0 months 11.53 4.06 0.01 19.54 3.51
ADBBþ autologous t> 9 months 5.40 6.79 0.43 8.03 18.82
ADBBþDFDBA t¼ 4.5–9.0 months 24.09 5.10 0.00 34.17 14.00
ADBBþDFDBA t> 9 months 6.77 6.45 0.30 5.97 19.51
Synthetic HA t< 4.5 months 13.56 8.56 0.12 30.47 3.36
Synthetic HA t¼ 4.5–9.0 months 0.91 5.49 0.87 11.78 9.95
Synthetic HA t> 9 months 9.35 8.20 0.26 25.55 6.85
Coral-derived HA t¼ 4.5–9.0 months 9.81 6.70 0.15 23.05 3.42
Coral-derived HA t> 9 months 4.11 10.33 0.69 16.30 24.52
b-TCP t¼ 4.5–9.0 months 3.35 4.40 0.45 12.06 5.35
B-TCP t> 9 months 11.84 11.24 0.29 34.06 10.39
b-TCPþ autologous t¼ 4.5–9.0 months 3.04 6.08 0.62 15.06 8.98
b-TCPþ autologous t> 9 months 16.98 10.13 0.10 37.01 3.05
Bioactive glassþ autologous t< 4.5 months 8.19 15.91 0.61 39.65 23.26
Bioactive glassþ autologous t¼ 4.5–9.0 months 7.76 7.38 0.29 22.34 6.83
Bioactive glassþ autologous t> 9 months 16.72 9.82 0.09 36.13 269
Reference group is autologous bone grafting and biopsy time (t) between 4.5 and 9.0 months.
Table 16. Summation of Regression Analysis 2
t< 4.5 compared to t¼ 4.5–9.0 t> 9.0 compared to t¼ 4.5–9.0
Effect 95% CI p-Value Effect 95% CI p-Value
Autologous 10.86 [2.41, 19.3] 0.02 9.52 [0.1, 19.14] 0.05
PRP 15.04 [13.62, 43.71] 0.27
MFDBA 6.74 [19.53, 33.02] 0.58 8.07 [15.1, 31.23] 0.46
ADBB 1.17 [12.87, 15.2] 0.86 6.19 [3.27, 15.65] 0.18
ADBBþ autologous 25.69 [6.84, 44.53] 0.01 5.40 [9.75, 20.54] 0.45
ADBBþDFDBA 6.77 [7.6, 21.15] 0.32
Synthetic HA 13.56 [32.64, 5.53] 0.14 9.35 [27.63, 8.93] 0.28
Phycogenic HA 4.11 [18.92, 27.14] 0.70
b-TCP 11.84 [36.91, 13.24] 0.32
b-TCPþ autologous 16.98 [39.58, 5.62] 0.12
Bioactive glassþ autologous 7.20 [31.12, 16.72] 0.52
CI, confidence interval.
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useful adjunctive therapy that results in an increased sur-
vival rate of implant in the grafted maxillary sinus.38 This
increase in implant survival could be explained by a higher
percentage of bone volume.38,112 However, our study shows
no significant effect, positive or negative, of the use of a
(non)-resorbable membrane over the lateral window on the
amount of TBV.
Conclusions
‘‘Particulate grafting,’’ ‘‘immediate and delayed implant
placement,’’ and ‘‘biopsy time’’ were determined as general
significant variables on the histomorphometric outcome of
TBV after sinus floor augmentation surgery using various
biomaterials. Allogenic, xenogenic, and alloplastic graft ma-
terials or combinations will result in a significant lower TBV
compared to autologous bone grafting. The addition of PRP
to an autologous bone graft in sinus augmentation has a
negative effect on the TBV. In the second analysis, invento-
rying the effect of ‘‘biopsy time’’ for autologous bone, the TBV
was significantly higher before 4.5 and after 9.0 months of
healing time compared to period in between. For bone
substitutes only the ADBB in combination with autologous
bone performed significant higher in the first 4.5 months.
Surprisingly, for all other bone substitutes no significant ef-
fect on TBV in time could be proven. On the basis of this
histomorphometric meta-analysis autologous bone grafting
results in the highest TBV and has still to be considered to be
the gold standard. All described bone graft substitutes
showed less TBV. However, it must be emphasized that
the consequence of the TBV for implant survival is still
unraveled yet.
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